BCRX vs QQQ Stock Comparison
BCRX currently leads QQQ in this stock comparison, with AIQ scores of 59 vs 46. The clearest difference is value, while QQQ has the stronger quality profile.
What is the main difference between BCRX and QQQ?
BCRX leads the current stock comparison as BioCryst Pharmaceuticals, Inc., with the clearest separation coming from value and the broader AIQ evidence mix.
AlgovestIQ AIQ Comparison
BioCryst Pharmaceuticals, Inc. vs Invesco QQQ Trust, Series 1
BCRX leads
BCRX leads by 13 AIQ points, primarily on Value and Risk Resilience, having only recently taken the lead back from QQQ.
Fragile: 3 of 4 evidence groups support BCRX, and the lead recently changed hands.
BioCryst Pharmaceuticals, Inc.
Invesco QQQ Trust, Series 1
The Algovestiq AIQ Score currently favors BCRX over QQQ, 59 versus 46 as of Nov 15, 2026. BCRX's advantage is driven primarily by stronger value and risk resilience, while QQQ holds the stronger quality profile. BCRX also shows the weaker technical structure relative to its 50-day moving average. 3 of 4 covered evidence groups favor BCRX today, and the comparison is rated Fragile on stability: the lead has already changed hands inside the comparison window. BCRX lead: Reversed — QQQ led by 3 AIQ points 30 sessions ago; BCRX now leads by 13.
Compare BioCryst Pharmaceuticals, Inc. and Invesco QQQ Trust, Series 1 across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.
Performance over time
Total return with distributions reinvested, from daily closes.
Total return comparison
Growth of $10,000, distributions reinvested
Split-adjusted closes; each distribution is reinvested at the close on its ex-dividend date. Taxes and trading costs are not modeled.
Compare BCRX and QQQ against another ticker
Open a multi-ticker workspace without changing this focused pair page.
AIQ Factor Divergence
Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.
- Value86 vs 13BCRX +73
- Quality64 vs 93QQQ +29
- Risk Resilience55 vs 31BCRX +24
- Momentum42 vs 33BCRX +9
3 of 4 evidence groups favor BCRX. BCRX’s edge is concentrated in value and risk resilience; QQQ keeps a meaningful quality edge.
What changed since the last close
Latest scored session 2026-11-13, compared against the prior scored session 2026-11-12.
Largest factor move: Quality +1, not enough on its own to move the overall score.
No signal started or stopped since the prior session; its 4 active signals are unchanged.
Largest factor move: Value +1
New signals
- Price Lost 200-Day MA — bearish, trend, long horizon
- Drawdown Recovery Signal — bullish, risk_regime, long horizon (-14.8%)
BCRX's lead widened by 1 AIQ point in the latest session.
Deeper signal detail for each name lives on its own signals page — BCRX and QQQ both carry a full feed there.
The central trade-off
BCRX (BioCryst Pharmaceuticals, Inc.): the stronger current systematic profile, led by value and risk resilience.
QQQ (Invesco QQQ Trust, Series 1): the counter-case, on quality, technicals.
Which one fits your objective
The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.
Balanced
BCRXBCRX on the overall AIQ Score, which weights Quality and Value most heavily.
Growth
EvenGrowth figures are not covered for both names.
Value
BCRXBCRX on the peer-relative Value factor, by 73 points.
Momentum
BCRXBCRX on the Momentum factor, by 9 points.
Lower downside
BCRXBCRX on Risk Resilience, by 24 points.
Analyst upside
EvenAnalyst targets are level or not covered for both names.
AIQ vs Wall Street
Where the systematic read and the analyst consensus line up — and where they do not.
| Measure | BCRX | QQQ | Note |
|---|---|---|---|
| Implied upside to target | +44.5% | — | Level |
| Target dispersion | 0% | — | Lower is tighter analyst agreement |
| Consensus | Buy | — | Context, not a primary driver |
| Analysts covering | 11 | — | Higher coverage generally improves confidence |
Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.
AIQ Agreement Matrix
3 of 4 covered evidence groups favor BCRX. A wide gap backed by one group is a weaker case than a narrow gap backed by five.
| Evidence group | Favors | Reading |
|---|---|---|
| AIQ Score | BCRX | 59 vs 46 |
| Fundamentals | Not covered | Not covered |
| Valuation | BCRX | Value 86 vs 13 |
| Technicals | QQQ | Price vs 50-day -7.6% vs -5.3%; vs 200-day -13.5% vs -0.3% |
| Risk Resilience | BCRX | Risk Resilience 55 vs 31 |
| Analyst expectations | Not covered | Not covered |
✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of BCRX and QQQ and are excluded from the count.
AIQ Decision Stability
The conclusion is sensitive to small changes. Treat the lead as provisional and watch the flip conditions below.
- The AIQ gap is wide at 13 points. (supports the conclusion holding)
- The lead has already changed hands inside the comparison window. (argues the conclusion is provisional)
- Signal direction runs against the verdict: the leader is net-bearish while the laggard is net-bullish. (argues the conclusion is provisional)
Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on BCRX.
How the comparison changed
120 daily snapshots · May 27 – Nov 13BCRX lead: Reversed — QQQ led by 3 AIQ points 30 sessions ago; BCRX now leads by 13.
- Today
- BCRX +13
- 59 vs 46
- 7 sessions ago
- BCRX +12
- 62 vs 50
- 30 sessions ago
- QQQ +3
- 60 vs 63
- 90 sessions ago
- BCRX +15
- 71 vs 56
The lead changed hands once in this window, most recently on Sep 30 when QQQ moved ahead of BCRX.
AIQ Signal Divergence
Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.
0 bullish / 2 bearish / 2 neutral
Only BCRX
- Death Cross Active — bearish, trend, long horizon (6.91%)
- ADX Trend Weakening — neutral, trend, medium horizon
- ATR Expansion - Breakout Mode — neutral, volatility, short horizon (4.55%)
- Downtrend Structure Active — bearish, trend, long horizon
2 bullish / 1 bearish, conflicted
Only QQQ
- Golden Cross Active — bullish, trend, long horizon (5.22%)
- Price Lost 200-Day MA — bearish, trend, long horizon
- Drawdown Recovery Signal — bullish, risk_regime, long horizon (-14.8%)
QQQ is conflicted, so the timing case there is weaker than the score alone suggests.
Price vs model alignment
Whether the latest session's price move confirms what the model did over the same session, or contradicts it.
Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price -0.91%, AIQ 0 points).
Price and the AIQ Score both moved down over the latest session (price -1.2%, AIQ -1 points).
What would flip this result
A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.
- 1QQQ closes the Value gap — currently 73 points behind, the largest single contributor to BCRX's edge.
- 2QQQ's Price Lost 200-Day MA resolves — a bearish trend rule currently active against it.
- 3BCRX starts generating bearish momentum or trend signals.
- 4A market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.
The full evidence
Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.
Fundamentals
Split| Metric | BCRX | QQQ |
|---|---|---|
| Revenue growth (YoY) | -17.4% | — |
| EPS growth (YoY) | -51.6% | — |
| Gross margin | 25.3% | — |
| Operating margin | -30.1% | — |
| Return on equity (TTM) | -9.5% | — |
| Debt to equity | -2.08 | — |
Performance
QQQ leads 5 of 6 windows| Metric | BCRX | QQQ |
|---|---|---|
| 1 week (5 sessions) | -1% | 3.6% |
| 1 month (20 sessions) | -2.3% | -4.2% |
| 3 months (63 sessions) | -23.4% | -6.8% |
| 6 months (126 sessions) | -15.6% | -4.1% |
| Year to date | -2.4% | 10.7% |
| 1 year (252 sessions) | 6% | 9.5% |
Technicals
QQQ has the stronger structure| Metric | BCRX | QQQ |
|---|---|---|
| RSI (14) | 40.7 | 42.8 |
| ADX (14) | 15.2 | 30.3 |
| Price vs 50-day | -7.6% | -5.3% |
| Price vs 200-day | -13.5% | -0.3% |
| Volatility (1M, annualized) | 45.2% | 35.4% |
Risk
BCRX is the more resilient| Metric | BCRX | QQQ |
|---|---|---|
| Beta | 0.65 | 1.46 |
| Sharpe ratio | 0.36 | 0.44 |
| Sortino ratio | 0.56 | 0.62 |
| Max drawdown | -32.2% | -14.8% |
| Current drawdown | -31.5% | -10.5% |
| Annualized volatility | 48.1% | 21.5% |
| Value at risk (95%) | -4.1% | -2% |
Straight answers
Each answer is regenerated from the current snapshot, not written once and left to age.
Which is better, BCRX or QQQ?
On the Algovestiq AIQ Score, BCRX is the stronger of the two as of Nov 15, 2026, scoring 59 against QQQ's 46. The edge comes from value and risk resilience. QQQ is not without a case — it holds the better quality profile, which matters more if that is the objective you are optimizing for. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.
Is BCRX or QQQ the better buy right now?
BCRX carries the stronger systematic profile as of Nov 15, 2026, and the comparison is rated Fragile — 3 of 4 covered evidence groups agree. A Fragile rating means the conclusion is sensitive: the lead has already changed hands inside the comparison window. Treat the lead as provisional.
Why does the AIQ Score favor BCRX over QQQ?
The composite weights Quality, Value, Momentum and Risk Resilience. BCRX leads Value by 73 points; QQQ leads Quality by 29 points; BCRX leads Risk Resilience by 24 points. Where the two split, the factor with the larger weight carries the result.
Which has more analyst upside, BCRX or QQQ?
Analyst price targets imply +44.5% upside for BCRX and not covered for QQQ. The model and the Street agree here, which is a broader base of evidence than either alone. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.
Which is better value, BCRX or QQQ?
BCRX is the better-valued of the two on the peer-relative Value factor. BCRX on the peer-relative Value factor, by 73 points. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.
Which has stronger growth, BCRX or QQQ?
Growth figures are not covered for both names. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.
Which has stronger momentum, BCRX or QQQ?
BCRX on the Momentum factor, by 9 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.
Which is riskier, BCRX or QQQ?
BCRX is the more resilient of the two, so the other name carries the higher downside risk. BCRX on Risk Resilience, by 24 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.
Is BCRX more profitable than QQQ?
Margin data is not comparable for both names in the current snapshot.
Is BCRX's lead over QQQ getting stronger or weaker?
BCRX lead: Reversed — QQQ led by 3 AIQ points 30 sessions ago; BCRX now leads by 13. This is measured from 120 daily comparison snapshots between 2026-05-27 and 2026-11-13. The lead has changed hands once in that window, most recently on 2026-09-30, when QQQ moved ahead of BCRX.
What would change the BCRX vs QQQ verdict?
The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: QQQ closes the Value gap — currently 73 points behind, the largest single contributor to BCRX's edge; QQQ's Price Lost 200-Day MA resolves — a bearish trend rule currently active against it; BCRX starts generating bearish momentum or trend signals; a market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.
What do the current signals say about BCRX and QQQ?
BCRX: 0 bullish / 2 bearish / 2 neutral. QQQ: 2 bullish / 1 bearish, conflicted. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on BCRX is Death Cross Active (bearish, long horizon). On QQQ it is Golden Cross Active (bullish, long horizon).
Continue your research
This page answers which of the two. These answer the questions on either side of it.
How this comparison is scored
The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.
The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.
How to use side-by-side comparison →This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.